Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

gainst products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. 

Contacts:

Onyx Pharmaceuticals, Inc.
Danielle Bertrand (media)
1-650-266-2114

Amgen
Ashleigh Koss, 1-805-313-6151 (media)
Arvind Sood, 1-805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20131107/LA12955LOGO)


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... Array Architects is proud of a 30-year ... nation's hospitals and health systems. It is a niche ... careers to the advancement of both the healthcare and ... field, Laura Silvoy has been chosen to share her ... Conference. , Laura will present her Process Simulation ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper ... challenges of becoming the first calibration laboratory in ... weights in the microgram range. National Metrology Institutes ... scientists involved in nanotechnology applications will benefit from ... calibration of weights in the range of 0.05 ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Inc. (NASDAQ: NBIX ) today announced its financial results ... the third quarter of 2011, the Company reported net income of ... net income of $3.3 million, or $0.06 per fully diluted share ... ended September 30, 2011, the Company reported a net income of ...
... I: High Blood Pressure , aka Hypertension ... expensive, and mostly ineffective.   Fortunately , ... by natural methods that are both effective, inexpensive, and risk free. ... can help reduce   Chronic Heart/Cardiovascular Disease patients, ...
... Oct. 31, 2011 iBio, Inc. (NYSE ... issuance from the United States Patent and Trademark Office ... Genes in Plants," that further extends iBio,s patent coverage ... technology owned by iBio was developed by scientists at ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2iBio Announces New US Patent for iBioLaunch™ Technology 2iBio Announces New US Patent for iBioLaunch™ Technology 3
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... Nov. 3, 2014  NeuroSigma ® , Inc. ... sciences company focused on commercialization of its non-invasive ... the treatment of neurological and neuropsychiatric disorders, announced ... has issued a Notice of Allowance for Mexican ... co-owned by NeuroSigma and the Regents of the ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... DCMay 28, 2008A 2008 American Society for Microbiology (ASM) ... to Marvin Whiteley, Assistant Professor, Molecular Genetics and Microbiology, ... Laboratories, the Merck Irving S. Sigal Memorial Award is ... instrumental in the early discovery of therapies to treat ...
... German . The sense of smell might ... fish or even mammals. This is the main conclusion of ... and her colleagues. The sense of smell in birds was, ... studies have shown that some bird species use their sense ...
... "Leatherback Turtle" you might think the sea turtles could stand ... them, and for more than a hundred million years, they ... of leatherbacks in the eastern Pacific Ocean has plummeted by ... many species that migrate across a vast ocean, pinpointing all ...
Cached Biology News:Do birds have a good sense of smell? 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 3Leatherback turtles' newly discovered migration route may be roadmap to salvation 4Leatherback turtles' newly discovered migration route may be roadmap to salvation 5Leatherback turtles' newly discovered migration route may be roadmap to salvation 6
Request Info...
... 5B15-5B-11E. Immunogen: Synthetic peptide derived from ... protein. Specificity: Specific for the ... Western blots it identifies the target band ... (positive controls: deglycosylated secreted media from primary ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: